🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Big News 🗞️🎉: EGFR Resisters is becoming an independent 501(c)(3) non-profit organization! Since 2017, we’ve united a global community of 6,000+ patients and caregivers, raised over $1M for research, and created essential resources for those impacted by EGFR-positive lung

🚨Calling all @asco #ASCO25 annual meeting attendees! Come join us in person for our annual #MedEd CoP event!! 🔔 Saturday May 31st 🔔 7:30-9:30 am 🔔 Room S103 ‼️Keynote speakers: TwoOncDocs and Oncology Brothers!! Can’t wait to see you there!! 🥰

All smiles at #ASCO25, kicking things off with the OncLive National Fellows Forum on Lung Cancer! Benjamin Levy Kristen A. Marrone, MD Eric K. Singhi, MD Narjust Florez, MD, FASCO Christine Garcia, MD, MPH Sandip Patel MD FASCO @ascocancer #LungCancer #LCSM #onclive #FellowsForum #cancerresearch

Thanks OncLive.com for this awesome program for fellows! The future of thoracic oncology is bright! #meded #ASCO25 Narjust Florez, MD, FASCO Sandip Patel MD FASCO Benjamin Levy Eric K. Singhi, MD Kristen A. Marrone, MD

The ASCO Ed Book is the highest-quality, peer-reviewed, free #oncology #MedEd ever. Whether or not you are attending #ASCO25, don’t miss out on this, #OncTwitter #MedTwitter, #MedStudentTwitter. Bookmark this tweet to keep the link handy: ascopubs.org/toc/edbk/curre… #OncoAlert

Congratulations to our 🌟 Johns Hopkins Hematology and Oncology Fellowship fellows Drs. Ferreira, Liang, Mo, Walsh and Zavras on their ASCO Conquer Cancer, the ASCO Foundation Young Investigator Awards. And to our alumna/phenomenal faculty member Marina Baretti on her CDA! So incredibly proud of their hard work & dedication 🤩🙌🏼

Congratulations to our 2025 ASCO Oncology Young Investigator Award recipients! 🎉 Phaedon D. Zavras Phaedon Zavras 🎉 Laura Walsh 🎉 Shirley Mo 🎉 Kai-li Liang Kai-li Liang 🎉 Michelle Ferreira And recent fellowship graduate and CDA recipient Marina Baretti Marina Baretti

The future of medical oncology is brighter than ever #ASCO2025 Marina Baretti Kristen A. Marrone, MD Kai-li Liang Phaedon Zavras

Don’t forget to check out all the #MedEd content at #ASCO25. Thanks to ASCO OncMedEdCoP for this curated list!

Lung cancer mortality at #ASCO2025: Are rural Americans left behind? Dena Rhinehart, MD (⭐️ Chief Fellow Johns Hopkins Hematology and Oncology Fellowship) from our policy team finds slower gains for younger adults & women Come check out Poster Bd 387 | Today, 130-430PM | Hall A UAB O'Neal Comprehensive Cancer Center Aakash Desai, MD, MPH, FASCO Gabrielle

Out now & open access in Nature Medicine concurrent with presentation at #ASCO2025 is NeoCOAST-2! I have been delighted to collaborate on the first platform neoadjuvant trial in lung cancer led by Dr. Tina Cascone nature.com/articles/s4159… ! #LCSM 1/6

Congrats to Patrick Forde #TinaCascone and the entire NEOCOAST2 team, the first platform neoadjuvant immunotherapy trial in NSCLC, with Ireland as a contributing site 🇮🇪 Nature Medicine MD Anderson Cancer Center Trinity St James's Cancer Institute #IrishLungCancerAlliance #LCSM

Congratulations to Kathryn Arbour Kathryn C. Arbour and colleagues showing activity of BMS-986504 in MTAP-deleted solid tumors, including lung and pancreas cancer. Memorial Sloan Kettering Cancer Center

Savannah Study of savo/osi vs osi alone for pts in 2nd line MET+ egfr+ nsclc clearly shows that maintaining EGFR TKI therapy is critical for best outcomes- in particular in CNS In other words osi seems to take the lion’s share of keeping the CNS progression free Benjamin Levy

Brava Patrick Forde, collaborators and patients! Amazing change forward ✨️

Dr. Jamie Chaft with NEOADAURA at #ASCO25. Neoadjuvant osimertinib alone or with chemo vs neoadjuvant chemo in NSCLC. MPR only 2% with chemo, vs 25% with osi, 26% with osi/chemo. pCR 9% osi, 4% osi/chemo. EFS better for pts who MPR - curious how adjuvant osi contributed to EFS.

Amazing lineup for this virtual event. Speakers include PIs of phase 3 IO trials across solid tumors Drs. Solange Peters Tom Powles John Heymach Ronan Kelly Tina Cascone Mark Yarchoan Grainne O'Kane translational scientists & FDA regulatory perspectives Sign up now! #LCSM

Impacts of co-mutations in oligometastatic and oligoprogressive non-small cell lung cancer with EGFR/ALK mutations—a narrative review of the current literature tlcr.amegroups.org/article/view/1… Oncogene Cancer Research ALK Positive EGFR Positive Lung Cancer UK

#vaping #VALI Vaping-Associated Lung Injury is real. If you have friends or family who use these, beware they are not without harm.

Our MD Anderson Cancer Center thoracic oncology rotation journal club for the fellows is about to be 🔥 🔥 #ASCO25